SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 17, 2003
ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware | 000-21429 | 04-3221586 | ||
|
||||
(State or other
jurisdiction of incorporation) |
(Commission File Number) | (I.R.S.
Employer Identification No.) |
19 Presidential Way Woburn, MA |
(Address of principal executive offices) |
01801 |
(Zip code) |
(781) 994-0300 |
(Registrants telephone number, including area code) |
Item 5. Other Events and Regulation FD Disclosure
On July 17, 2003, ArQule, Inc. announced that it signed a definitive agreement to acquire Cyclis Pharmaceuticals, Inc. The press release announcing the execution of the agreement is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Text of Press Release, dated July 17, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARQULE, INC. (Registrant) |
||||
/s/ Stephen A. Hill Stephen A. Hill President and Chief Executive Officer |
||||
Date: | July 18, 2003 |